论文部分内容阅读
目的探讨后腹腔镜下以及开放性肾癌根治术治疗局限性肾癌的临床效果。方法 82例局限性肾癌患者依据治疗方法不同分为对照组和观察组,各41例。观察组采用后腹腔镜肾癌根治术治疗;对照组采用传统开放肾癌根治术治疗。观察对比两组患者术中出血量、住院时间、术后恢复正常活动时间、术后恢复进食时间及不良反应发生情况。结果观察组局限性肾癌患者手术时间为(104.9±11.1)min,术中出血量为(105.3±25.4)ml,住院时间为(4.3±1.3)d,手术后恢复正常活动时间为(6.2±2.3)d,术后恢复进食时间为(1.3±0.4)d少于对照组的(112.3±11.3)min、(172.2±43.3)ml、(8.9±2.1)d、(12.9±1.9)d、(3.3±1.3)d,差异有统计学意义(P<0.05)。观察组并发症发生率7.32%低于对照组的24.39%,差异有统计学意义(P<0.05)。结论临床对局限性肾癌患者,选择后腹腔镜下肾癌根治术的方法进行治疗,可以将患者手术后恢复正常活动时间显著缩短,最终显著提高局限性肾癌患者的生活质量。
Objective To investigate the clinical effect of retroperitoneoscopic and open radical nephrectomy in the treatment of localized renal cell carcinoma. Methods 82 cases of localized renal cell carcinoma patients were divided into control group and observation group according to different treatment methods, 41 cases in each. The observation group was treated with retroperitoneal laparoscopic radical nephrectomy; the control group was treated with open radical nephrectomy. Observe and compare the two groups of patients intraoperative blood loss, hospital stay, postoperative recovery to normal activity time, postoperative recovery of eating time and adverse reactions. Results The operative time was (104.9 ± 11.1) min in the patients with limited renal cell carcinoma in observation group, the blood loss was (105.3 ± 25.4) ml and the hospital stay was (4.3 ± 1.3) days, and the time to normal activity after operation was 6.2 ± (1.3 ± 0.4) d less than the control group (112.3 ± 11.3) min, (172.2 ± 43.3) ml, (8.9 ± 2.1) d, (12.9 ± 1.9) d and 3.3 ± 1.3) d, the difference was statistically significant (P <0.05). The incidence of complications in the observation group was 7.32% lower than that in the control group (24.39%), the difference was statistically significant (P <0.05). Conclusions The clinical treatment of patients with locally advanced renal cell carcinoma and selective retroperitoneal laparoscopic radical nephrectomy can shorten the time to return to normal after surgery and ultimately improve the quality of life of patients with localized renal cell carcinoma.